Product

Company

Clareo Health | OM336 in Autoimmune Cytopenias

NCT07083960·7 sites·ClinicalTrials.gov

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Lakefront Biotherapeutics West LLC

An open-label, multicenter, ascending dose study, evaluating safety, tolerability, and PK/ADA of OM336 in autoimmune cytopenias.

Age

18–75

Sex

ALL

Healthy volunteers

Not accepted

Previous treatment with a BCMA-targeted therapy
Clinically significant infection within 3 months of screening
Major surgery or splenectomy within 3 months of screening or planned during the study
Pregnant or breastfeeding

The record

StatusRecruiting

PhasePhase 1

Taking part32

StartedAug 2025

UpdatedSep 3, 2026

Conditions

Where7